Serious Infections in the Critical Care Setting (CE)
- CreditType
- CE
- Credit Amount
- 1
- Release Date
- 07/01/2010
- Expiration Date
- 06/30/2011
- Activity Type
- Compendium
This CE activity is jointly sponsored by Albert Einstein College of Medicine, Montefiore Medical Center, the West Virginia University School of Pharmacy Office of Continuing Education, and Asante Communications, LLC.
This program is endorsed by the Society of Infectious Diseases Pharmacists (SIDP).
Supported by an educational grant from Ortho-McNeil™, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., administered by Ortho-McNeil Janssen Scientific Affairs, LLC.
Activity Goal
The goal of this knowledge-based activity is to educate healthcare professionals on current strategies for the prevention and control of serious bacterial infections in the critical care setting, particularly with respect to potentially endemic multidrug-resistant (MDR) organisms.
Intended Audience
This activity is intended for pharmacists involved in the prevention and control of serious bacterial infections in the critical care setting.
There are no prerequisites for this educational activity.
Statement of Need
Hospital-acquired infections (HAIs) impose a significant burden on patients, prescribers, and the healthcare system. Increasingly troublesome are MDR bacteria. Antibiotic prescribing is often inappropriate across treatment settings, particularly in critical care, where the risk of serious complications is elevated, comorbidities and presence of MDR pathogens often confound treatment, and the margin for error is exceedingly small. Drug resistance will continue to be a virtually inevitable consequence of antibiotic therapy absent rigorous source control programs and care pathways governing initial selection of an appropriately broad-spectrum antibiotic, pathogenspecific de-escalation, and timely cessation of treatment.
Learner's Gap
Healthcare institutions should adapt evidence-based guidelines built on local microbiology. The proposed activity addresses strategies for individualizing infection surveillance protocols and management plans based on local microbiology. The activity will thereby facilitate efforts to tailor prevention and control measures on a hospital-by hospital basis. Elements of an effective antibiotic stewardship program, anchored by an infectious diseases specialist and clinical pharmacist with infectious diseases training, will also be addressed.
Learning Objectives
At the completion of this initiative, participants should be better prepared to:
- Stratify patients with hospital-acquired infections for risk of multidrug-resistant, Gram-negative and/or Gram-positive pathogens
- Select appropriate empiric antibiotic therapy based, in part, on comprehensive patient assessment, infection type, and local susceptibility data
- Incorporate pharmacokinetic and pharmacodynamic data to optimize antibiotic dosing strategies
- De-escalate broad-spectrum antibiotic therapy to pathogen-directed agents based in part on culture information
- Implement evidence-based, source control strategies and institutional best practices to minimize the threat of multidrug-resistant organisms
Accreditation Statement and Credit Designation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Albert Einstein College of Medicine, Montefiore Medical Center, the West Virginia University School of Pharmacy Office of Continuing Education (CE), and Asante Communications, LLC.
The West Virginia University School of Pharmacy is accredited by the Accreditation Council of Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program (ACPE # 0072-9999-10-069-H01-P) is a knowledge-based program and approved for a total of 1.0 hours or 0.1 CEU of continuing pharmacy education (CPE) credit.
Method of Participation
To obtain Continuing Pharmacy Education (CPE) credit, please complete the posttest, activity evaluation form and self-report credit form.
Conflict of Interest Statement
The Conflict of Interest Disclosure Policy of Albert Einstein College of Medicine and West Virginia University School of Pharmacy Office of Continuing Education requires that faculty participating in any CME/CPE activity disclose to the audience any relationship(s) with a pharmaceutical, product, or device company. Presenters whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present.
Albert Einstein College of Medicine and West Virginia University School of Pharmacy Office of Continuing Education also require that faculty participating in any CME/CPE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Faculty and reviewers of this program have indicated the following disclosure
information:
Sandy J. Estrada, PharmD, BCPS
Has no conflict(s) of interest to report
Lisa G. Jones, RN, MS, CCRN
Has no conflict(s) of interest to report
Marin H. Kollef, MD
Astellas (Consultant, Speakers Bureau); AstraZeneca (Consultant, Speakers Bureau); Merck (Consultant, Speakers Bureau); Pfizer (Consultant, Speakers Bureau)
Ira Leviton, MD
Astellas (Consultant, Speakers Bureau); Cubist (Consultant, Speakers Bureau); Pfizer (Consultant, Speakers Bureau); Wyeth (Consultant, Speakers Bureau)
Virginia G. Scott, PhD, MS, RPh
Has no conflict(s) of interest to report
Andrew F. Shorr, MD, MPH, FCCP
Astellas (Consultant, Grant/Research, Speakers Bureau); Bard (Consultant, Grant/Research); Boehringer Ingelheim (Speakers Bureau); Cadence (Consultant); Canyon (Consultant); Cerexa (Consultant); Covidien (Speakers Bureau); Eli Lilly (Consultant); GlaxoSmithKline (Consultant, Grant/Research, Speakers Bureau); J&J (Consultant, Grant/Research, Speakers Bureau); Pfizer (Consultant, Grant/ Research, Speakers Bureau); Pulmatrix (Consultant); Sanofi-Aventis (Grant/Research, Speakers Bureau); Theravance (Consultant, Grant/Research)
Albert Einstein College of Medicine and Montefiore Medical Center, Center for Continuing Medical Education (CCME) staff, the staff of West Virginia University School of Pharmacy Office of Continuing Education, and the staff of Asante Communications, LLC, have no conflicts of interest with commercial interests related directly or indirectly to this educational activity.
Alan Morrice, PhD, Scientific Supervisor, Asante Communications, LLC
Has no conflicts of interest with commercial interests related directly or indirectly to this educational activity.
Steven Jay Feld of Albert Einstein College of Medicine or a member of his household owns securities in Bioheart, Inc., Chelsea Therapeutics, Inc., and Pharmacopeia, Inc.
Copyright Information
© 2010 Albert Einstein College of Medicine and Montefiore Medical Center, West Virginia University School of Pharmacy, and Asante Communications, LLC. All rights reserved. No part of this syllabus may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embedded in articles or reviews.
Faculty
|
|
e-Newsletter
|
